



UNIVERSITY OF LEEDS

This is a repository copy of *Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/216164/>

Version: Supplemental Material

Article:

Mukherjee, S., Qi, C., Shaw, R. et al. (20 more authors) (2024) Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. *European Journal of Cancer*, 209. 114236. ISSN 0959-8049

<https://doi.org/10.1016/j.ejca.2024.114236>

© 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. This is an author produced version of an article published in *European Journal of Cancer* made available under the CC-BY-NC-ND 4.0 license (<http://creativecommons.org/licenses/by-nc-nd/4.0>) in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

FIGURES




Figure 1: CONSORT flow diagram of stage 2 of the SCALOP-2 trial.




Figure 2: Kaplan Meier estimates for stage 2 patients receiving chemoradiotherapy of (A) overall survival by standard versus high dose radiation and (B) progression free survival by nelfinavir usage.




Figure 3: Mean EORTC-PAN26 score prior to, immediately, 6-, 18- and 28- weeks following standard (50.4Gy in 28 fractions) and high (60Gy in 30 fractions) dose chemoradiotherapy. Error bars indicate the 95% confidence interval.






Figure 4: Mean EORTC-PAN26 score prior to, to immediately, 6-, 18- and 28- weeks following chemoradiotherapy with and without concurrent nelfinavir. Error bars indicate the 95% confidence interval